

Special Issue

PROomics: Patient Reported Outcome (PRO) and Self-Tracking for Personalized Medicine

Message from the Guest Editor

What is more personalized than including individual observations, personal feelings, and mood, as well as self-tracked data into the medical decision process? Individual observations, personal feelings, and mood constitute the so-called Patient-Reported Outcome (PRO). In daily life, we are facing a constantly growing number of PRO measurements based on digital applications. At the same time, the amount of medically useful data coming from self-tracking or wearable devices is rapidly increasing as well. PRO and self-tracking data represent a new class of medically valuable data. We have named them PROomics. As there are few or nearly no models on how to incorporate PROomics information into personalized medicine, we would like to invite researchers working in this field to submit their manuscripts to this Special Issue. PROomics means looking at patients' documented and recorded data beyond a single questionnaire and making them available for research and medical care. Manuscripts of interest can range from basic research to clinical routine.

Guest Editor

Dr. Beth C. Bock

Centers for Behavioral & Preventive Medicine The Miriam Hospital Coro Building, Suite 309 One Hoppin Street, Providence, RI 02903, USA

Deadline for manuscript submissions

closed (15 August 2020)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/39497

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).